Application of hyperoside in preparation of medicine for inhibiting chronic myelogenous leukemia
By developing hypericin drugs, using targeted ferrosin death mechanisms to inhibit the proliferation and migration of chronic myeloid leukemia cells, the problem of resistance to tyrosine kinase inhibitors is solved, and a new treatment plan is provided. Significantly inhibits the growth and apoptosis of leukemia cells.
Patent Information
- Application Number
- CN202410947418.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-12
AI Technical Summary
In the treatment of chronic myeloid leukemia, the resistance of tyrosine kinase inhibitors reduces the therapeutic effect of anti-leukemia, resulting in many patients not being able to benefit from existing treatments, lacking new targets and effective treatment options.
Develop Hyperoside drugs to inhibit the proliferation, migration and apoptosis of chronic myeloid leukemia cells by targeting the iron death mechanism, as a new dosing regimen for the treatment of chronic myeloid leukemia.
Hyperoside significantly inhibits the vitality and proliferation ability of K562 and Meg-01 cells, induces apoptosis, and effectively inhibits the growth and migration of chronic myeloid leukemia cells by increasing intracellular oxidative stress and ferrous death, providing a new Clinical treatment ideas.
Smart Images

Figure CN118924774A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular, relates to the application of flavonoid drug hyperoside in the preparation of drugs for inhibiting chronic myeloid leukemia. Background Art
[0002] Chronic myelogenous leukemia (CML) is a clonal myeloid neoplasm with uncontrolled proliferation of myeloid cells at every stage of differentiation. CML can be divided into three stages, beginning with the chronic phase (CP), which is characterized by a significant increase in myeloid precursor cells and lasts for about 3-5 years. In the absence of therapeutic intervention or in the case of refractory disease after 3-18 months, the disease spontaneously progresses to the accelerated phase (AP) and finally to the highly aggressive blast crisis (BC), with rapid expansion of primary myeloid cells and spread to the circulation. CML accounts for about 14% of newly diagnosed leukemia cases in adults. CML was the first cancer to be found to have an abnormal link between chromosomes, also known as the Philadelphia (Ph) chromosome, due to a reciprocal translocation (t9;22)(q34;q11) between the Abelson murine leukemia virus (ABL) gene on chromosome 9 and the breakpoint cluster region (BCR) on chromosome 22. BCR-ABL 1 promotes the survival and self-renewal of CML leukemia stem cells (LSCs) by activating various signaling molecules and pathways downstream of the BCR-ABL protein, which then differentiate into abnormal hematopoietic subpopulations and resist apoptosis, thereby promoting the occurrence of leukemia.
[0003] Chemotherapy is considered the most effective treatment for CML. Since the 2000s, tyrosine kinase inhibitors (TKIs) such as imatinib (IM) have been used as first-line treatment drugs. However, primary and secondary resistance to TKIs reduces the anti-leukemia therapeutic effect. Therefore, many CML patients cannot benefit from TKI treatment due to drug intolerance or resistance. This has become a major problem in clinical treatment, so elucidating its resistance mechanism and finding new targets need to be broken through.
[0004] In recent decades, extracting effective active ingredients from traditional Chinese medicine has become an alternative therapy to traditional treatment. Therefore, the inventors of this application experimentally studied the regulatory role of hyperoside in the occurrence and development of chronic myeloid leukemia. Further cell experiments and RNA-Seq proved that hyperoside can inhibit chronic myeloid leukemia by targeting ferroptosis at the cellular level. Summary of the invention
[0005] In view of the above problems, the present invention aims to provide the use of hyperoside in the preparation of drugs for inhibiting chronic myeloid leukemia. The research and development of Hyperoside drugs provides a new idea for the clinical development of drug administration regimens for treating chronic myeloid leukemia.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] The first aspect of the present invention provides the application of the developed Hyperoside drugs in the preparation of drugs for treating and / or preventing chronic myeloid leukemia.
[0008] Furthermore, hyperoside is used in the preparation of drugs for inhibiting the activity and migration ability of chronic myeloid leukemia cells.
[0009] Furthermore, the invention relates to the use of hyperoside in the preparation of a drug for inhibiting the proliferation of chronic myeloid leukemia cells.
[0010] Furthermore, the invention relates to the use of hyperoside in the preparation of a drug for inhibiting apoptosis of chronic myeloid leukemia cells.
[0011] The chronic myeloid leukemia cells include K562 and Meg-01. The chronic myeloid leukemia cells described in the present invention are not limited to K562 and Meg-01.
[0012] Hyperoside was used in a concentration gradient of 0, 0.5, 1.0 and 2.0 mM, and intervened for different time periods of 24 and 48 h to observe the ability of Hyperoside to affect the proliferation and growth of CML cells. The concentration of Hyperoside used in the present invention is not limited to 0.5-2 mM.
[0013] The preferred concentration of Hyperoside is 2.0 mM. When the concentration of Hyperoside is 0.5 mM, it has already exerted a significant ability to inhibit the proliferation and growth of chronic myeloid leukemia cells. Therefore, those skilled in the art should be aware that the concentration of Hyperoside described in the present invention is not limited to 0.5-2 mM.
[0014] The second aspect of the present invention provides the use of Hyperoside drugs in the preparation of drugs for treating and / or preventing chronic myeloid leukemia by targeting ferroptosis.
[0015] The main target of hyperoside in the preparation of drugs for inhibiting the growth of chronic myeloid leukocytes is related to ferroptosis.
[0016] Furthermore, the RNA-seq sequence of K562 screened out that the target genes SLC7A11 and Gpx4 of Hyperoside inhibited chronic myeloid leukemia cells and were significantly downregulated, which was related to ferroptosis;
[0017] Furthermore, various cell death inhibitors were selected, including Z-VAD-FMK (apoptosis inhibitor), necrosulfonamide (necrosis inhibitor), 3-Mmethyladenine (3-MA, autophagy inhibitor), and Fer-1 (ferroptosis inhibitor) to investigate the effects of Hyperoside on inhibiting CML cell viability, and to explore whether Hyperoside inhibits CML disease progression mainly through ferroptosis.
[0018] Furthermore, Hyperoside can enhance lipid peroxidation and ROS levels in K562 and Meg-01 cells and increase the level of intracellular oxidative stress.
[0019] Furthermore, Hyperoside promoted Fe2+ accumulation in K562 and Meg-01 cells.
[0020] Furthermore, the effect of Hyperoside on the mitochondrial structure of K562 and Meg-01 cells;
[0021] Therefore, hyperoside can be used in the preparation of drugs that enhance lipid peroxidation and ROS levels in chronic myeloid leukemia cells and increase intracellular oxidative stress levels.
[0022] Hyperoside can be used in the preparation of drugs for enhancing Fe2+ accumulation in chronic myeloid leukemia cells.
[0023] Hyperoside can be used in drugs to improve the mitochondrial structure of chronic myeloid leukemia cells
[0024] The beneficial effects of the present invention include at least: the effect of Hyperoside on the growth of CML cells is disclosed: Hyperoside can inhibit the cell viability of K562 and Meg-01 cells and inhibit their migration, Hyperoside can inhibit the proliferation ability of K562 and Meg-01 cells, and Hyperoside can induce apoptosis of K562 and Meg-01 cells. The inhibitory effect of Hyperoside on chronic myeloid leukemia cells is related to ferroptosis. Hyperoside can inhibit the growth of CML cells by promoting the occurrence of ferroptosis. A new idea is provided for the clinical development of a dosing regimen for the treatment of chronic myeloid leukemia. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The embodiments of the present invention are described in detail below with reference to the accompanying drawings, wherein:
[0026] Figure 1 Hyperoside was shown to inhibit the viability and migration ability of CML cells.
[0027] A. CCK8 detected the viability of K562 cells after 24h intervention with different concentrations of Hyperoside (0, 0.5, 1 and 2mM).
[0028] B. CCK8 detected the viability of Meg-01 cells after 24h intervention with different concentrations of Hyperoside (0, 0.5, 1 and 2mM).
[0029] C. CCK8 detected the viability of K562 cells after intervention with different concentrations of Hyperoside (0, 0.5, 1 and 2 mM) for 24 h and 48 h respectively.
[0030] D. CCK8 detected the viability of Meg-01 cells after intervention with different concentrations of Hyperoside (0, 0.5, 1 and 2 mM) for 24 h and 48 h respectively.
[0031] E. Transwell assay was used to detect the migration ability of K562 and Meg-01 cells after 24h intervention with different concentrations of Hyperoside (0, 0.5, 1 and 2 mM).
[0032] F. Quantitative results of K562 and Meg-01 cell migration ability.
[0033] Figure 2 Hyperoside was shown to inhibit the proliferation of CML cells.
[0034] A. Fluorescent staining of EdU-594 cell proliferation.
[0035] B. Quantitative results of EdU-positive cell rate in K562 cells.
[0036] C. Fluorescent staining of EdU-594 cell proliferation.
[0037] D. Quantitative results of the EdU-positive cell rate in Meg-01 cells.
[0038] Figure 3 Hyperoside was shown to induce apoptosis in CML cells.
[0039] A. Flow cytometry was used to detect the apoptosis rate of K562 cells after 24h intervention with different concentrations of Hyperoside (0, 0.5, 1 and 2mM).
[0040] B. Statistical graph of apoptosis ratio of K562 cells.
[0041] C. Flow cytometry was used to detect the apoptosis rate of Meg-01 cells.
[0042] D. Statistical graph of apoptosis ratio of Meg-01 cells.
[0043] EF.Western blotting was used to detect the expression levels of apoptosis-related proteins such as Bax, Bcl-2, and Caspase-3 in K562 cells under the action of different concentrations of Hyperoside (0, 0.5, 1, and 2 mM) and their quantitative results.
[0044] GH.Western blotting was used to detect the expression levels and quantitative results of apoptosis-related proteins such as Bax, Bcl-2, and Caspase-3 in Meg-01 cells under the action of different concentrations of Hyperoside (0, 0.5, 1, and 2 mM).
[0045] Figure 4 Shows transcriptome sequencing of K562 cells and screening of target genes.
[0046] A. PCA plot of RNA-seq sequencing.
[0047] B. KEGG pathway enrichment map.
[0048] C. Volcano map.
[0049] D. SLC7A11 mRNA levels in sequencing data.
[0050] E. Gpx4 mRNA levels in sequencing data.
[0051] F. q-PCR detection of SLC7A11 mRNA levels in K562 cells.
[0052] G. q-PCR detection of Gpx4 mRNA levels in K562 cells.
[0053] H. SLC7A11 and Gpx4 protein levels in K562 and Meg-01 cells under different treatments.
[0054] I. Quantitative analysis of SLC7A11 protein levels in K562 and Meg-01 cells under different treatments.
[0055] J. Quantitative analysis of Gpx4 protein levels in different treatment groups in K562 and Meg-01 cells.
[0056] Figure 5 It showed that the effect of Hyperoside on CML cell viability was mainly related to ferroptosis.
[0057] A. CCK8 detected the viability of K562 cells after 24h intervention with different concentrations of Hyperoside (0, 0.5, 1 and 2mM) combined with different inhibitors.
[0058] B. CCK8 detection of Meg-01 cell viability after 24h intervention with different concentrations of Hyperoside (0, 0.5, 1 and 2 mM) combined with different inhibitors
[0059] Figure 6 Hyperoside was shown to enhance lipid peroxidation and ROS levels in CML cells.
[0060] A. C11-BODIPY was used to detect the level of lipid peroxidation in K562 cells.
[0061] B. ROS levels in K562 cells.
[0062] C. Quantitative analysis of fluorescence intensity of lipid peroxidation and reactive oxygen species levels in K562 cells.
[0063] D. C11-BODIPY detected the level of lipid peroxidation in Meg-01 cells.
[0064] E. ROS levels in Meg-01 cells.
[0065] F. Quantitative analysis of fluorescence intensity of lipid peroxidation and reactive oxygen species levels in Meg-01 cells.
[0066] G. Analysis of NADPH / NADP+ ratio in K562 and Meg-01 cells.
[0067] H. Analysis of GSH / GSSG ratio in K562 and Meg-01 cells.
[0068] I. MDA levels of K562 and Meg-01 cells.
[0069] Figure 7 Hyperoside was shown to cause Fe2+ accumulation in CML cells.
[0070] A. FerroOrange detects the intracellular Fe2+ level in K562 cells.
[0071] B. Quantitative analysis of intracellular Fe2+ levels in K562 cells.
[0072] C. FerroOrange detected the intracellular Fe2+ level in Meg-01 cells.
[0073] D. Quantitative analysis of intracellular Fe2+ levels in Meg-01 cells.
[0074] Figure 8 Shows the effect of Hyperoside on the mitochondrial structure of K562 and Meg-01 cells.
[0075] A. Mitosox detects mitochondrial reactive oxygen species in K562 cells.
[0076] B. Mitosox detects mitochondrial reactive oxygen species in Meg-01 cells.
[0077] C. Quantitative analysis of Mitosox fluorescence intensity in K562 cells.
[0078] D. Quantitative analysis of Mitosox fluorescence intensity in Meg-01 cells.
[0079] E. Changes in mitochondrial structure of K562 cells.
[0080] F. Changes in mitochondrial structure of Meg-01 cells. DETAILED DESCRIPTION
[0081] The present invention is further described in detail below in conjunction with specific implementation modes, so that those skilled in the art can implement it according to the description.
[0082] Example
[0083] The examples are provided to better illustrate the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art may make non-essential improvements and adjustments to the implementation scheme according to the above invention content, which still fall within the protection scope of the present invention.
[0084] The terms used herein are only used to describe specific embodiments and are not intended to limit the present disclosure. Unless the context has a significantly different meaning, expressions in the singular include expressions in the plural. As used herein, it should be understood that terms such as "include", "have", "include" are intended to indicate the presence of features, numbers, operations, components, parts, elements, materials or combinations. The terms of the present invention are disclosed in the specification, and are not intended to exclude the possibility that one or more other features, numbers, operations, components, parts, elements, materials or combinations thereof may exist or may be added. As used herein, " / " may be interpreted as "and" or "or", depending on the circumstances.
[0085] In order to better understand the present invention, the content of the present invention is further explained below in conjunction with specific examples, but the content of the present invention is not limited to the following examples.
[0086] In the embodiments of the present invention, the preparation or related detection method involved is carried out according to the following steps:
[0087] The embodiment of the present invention provides an application of Hyperoside in preparing a drug for inhibiting CML.
[0088] In some specific embodiments, the above application may include: application of Hyperoside in the preparation of drugs for inhibiting CML. It should be noted that Hyperoside can inhibit the growth of CML (K562, Meg-01) cells, so it can be prepared into a drug for treating CML.
[0089] In the embodiments of the present invention, the preparation or related detection method involved is carried out according to the following steps:
[0090] 1. Cell culture: Select human chronic myeloid leukemia cell lines (K562, Meg-01), select cells with good growth, closely observe the cell density, and change the medium after it turns yellow. Spray it with alcohol and place it in a clean bench. Mix it with a 1ml gun tip and transfer it to a 15ml centrifuge tube at 1000rpm for 5min. After centrifugation, discard the supernatant, add complete medium to resuspend, transfer it to a T25 culture flask, and continue to culture it in the incubator.
[0091] 2. Cell passaging: After observing under a microscope and the cell density reaches 80%-90%, carry out cell passaging and culture. Place the cells in an ultra-clean workbench, mix them by pipetting, and inoculate them into new T25 culture flasks at a ratio of 1:2-1:3. Add new complete culture medium to make up to 5 ml and continue to culture them in the incubator.
[0092] 3. CCK-8 assay to detect cell viability in each group
[0093] (1) Take K562 and Meg-01 cells that are growing well and in the logarithmic growth phase and place them in a 1.5 ml centrifuge tube. Centrifuge at 1000 rpm for 5 min and discard the supernatant. Add 1 ml of culture medium to resuspend the cells and count them. Inoculate them in a 96-well plate at 1-2×104 cells / well.
[0094] (2) Hyperoside at different concentrations (0, 0.5, 1, and 2 mM) was added, and on this basis, various cell death inhibitors were added; Z-VAD-FMK (apoptosis inhibitor), Necrosμlfonamide (necrosis inhibitor), 3-Mmethyladenine (3-MA, autophagy inhibitor), Fer-1 (ferroptosis inhibitor), and the cells were exposed to the hyperoside for 24 h, or different concentrations of hyperoside were used for different exposure times (24 h and 48 h).
[0095] (3) After the hyperoside drug action time is reached, 10 μl of CCK-8 solution is added to each well, mixed by the "cross shaking method", and the 96-well plate is placed in a 37°C; 5% CO2 incubator for incubation for 2-4 hours. The absorbance (optical desity, OD) at a wavelength of 450 nm is detected using a multifunctional microplate reader.
[0096] (4) Calculate the growth survival rate of each group of cells = [(AS-AB) / (AC-AB)] × 100%
[0097] AS (experimental wells): Contains complete culture medium for cells, drugs and CCK8 reagent.
[0098] AC (control wells): contain complete culture medium and CCK8 reagent for cells.
[0099] AB (blank wells): contain complete culture medium and CCK8 reagent.
[0100] 4. EDU-594 kit to detect cell proliferation:
[0101] (1) An appropriate number of cells were cultured in a six-well plate. After the cells were cultured overnight and restored to normal state, different concentrations of hyperoside (0, 0.5, 1, 2 mM) were added to each well to intervene in K562 cells or Meg-01 cells for 24 h.
[0102] (2) The EDU working solution was diluted to 1× with culture medium, and then the cells were collected and centrifuged at 1000 rpm for 5 min. The cells were resuspended with 1× EDU working solution and incubated with K562 cells or Meg-01 cells for 2 h.
[0103] (3) After EDU labeling, collect the cells, centrifuge at 1000 rpm for 5 min, discard the supernatant, and wash the cells with PBS (2-3 times). Count the cells and dilute them with PBS.
[0104] (4) Take 20 μL of cell suspension for slide spreading and dry in the dark at room temperature.
[0105] (5) Add fixative and fix at room temperature for 10-15 minutes. After fixation, place the cells in a humidified chamber.
[0106] (6) Remove the fixative solution and wash three times with an appropriate amount of washing solution (PBS containing 3% BSA), each time for 3-5 minutes.
[0107] (7) Add permeabilization solution (0.3% TritionX-100 in PBS) and permeabilize for 15 min at room temperature.
[0108] (8) Wash with washing solution (PBS containing 3% BSA) for 3 times, each wash for 3-5 minutes.
[0109] (9) Add 20 μl of DAPI staining solution to the slide, incubate at room temperature for 10 min to stain the nucleus, and then wash three times with washing solution, each time for 3-5 min.
[0110] (10) After the slide is dried, add a drop of mounting medium and cover the cell area with a cover slip. Observe under a microscope and randomly take photos of more than 3 different fields of view. Use Image J software to count the positive cells.
[0111] 5. Transwell assay to detect CML cell migration ability:
[0112] (1) Place logarithmically growing CML cells in a 15 ml centrifuge tube and centrifuge at 1000 rpm for 5 min. Add 1 ml of complete medium, resuspend, and count.
[0113] (2) 200 μl of cell suspension (2-4×104) was inoculated into serum-free RPMI-1640 medium in the upper chamber, and 600-800 μl of RPMI-1640 medium containing 10% FBS and different concentrations of hyperoside (0, 0.5, 1, 2 mM) was added to the lower chamber.
[0114] (3) After culturing in the incubator for 24 h, the Transwell chamber was removed, the culture medium in the chamber was discarded, the chamber was placed in 4% paraformaldehyde, fixed for 30 min, and washed 2-3 times with PBS.
[0115] (4) Add 500 μl of 0.1% crystal violet to the chamber for staining for 10-20 min and wash with PBS 2-3 times.
[0116] (5) Then, use a cotton swab to gently wipe the unpenetrated cells on the upper layer of the chamber. After drying appropriately, observe and photograph more than three different fields of view under a microscope and analyze them using Image J software.
[0117] 6. Annexin V-FITC / PI double staining cell apoptosis kit, flow cytometry detection of apoptosis rate in each group:
[0118] (1) Collect cells from different treatment groups and centrifuge at 1000 rpm for 5 min. Discard the supernatant and wash twice with PBS. After the last centrifugation, resuspend and count with PBS. Take (1-5)×105 cells from each group.
[0119] (2) Add 500 μl of 1× Annexin V Buffer to suspend the cells.
[0120] (3) Add 5 μl of Annexin v-FITC and mix well. Then add 5 μl of Propidium Iodide and mix gently. Incubate at room temperature in the dark for 20-30 min.
[0121] (4) After staining, the cells were detected using a flow cytometer (FC500 flow cytometer) within one hour.
[0122] 8. Detection of protein levels by Western blotting:
[0123] (1) Protein sample preparation
[0124] After 24h of intervention of CML cells with hyperoside at different concentrations (0, 0.5, 1, and 2mM), the cells were collected by centrifugation, resuspended and washed with PBS, centrifuged at 1000rpm for 5min, and the supernatant was discarded, and repeated 2-3 times. According to the configuration of RIPA lysis buffer: protease inhibitor: phosphatase inhibitor = 100:1:1, 250μl lysis buffer was added to every 1×106 cells, mixed by vortex oscillation, vortex oscillation for 2min, ice bath for 10min, and repeated 3 times to fully lyse the cells. The cells were then lysed by ultrasonic disruptor. After ultrasonication, centrifuged at 12000rpm for 20min, the supernatant was collected, and the whole operation was carried out on ice. The supernatant volume was recorded and the protein concentration was determined.
[0125] (2) Protein concentration determination
[0126] Determine protein concentration using the BCA method: prepare BCA working solution; mix solution A: solution B at a ratio of 50:1, total BCA working solution volume = (standard + sample to be tested) × number of repetitions × BCA working solution required for each sample (add 200 μl BCA working solution to each sample in a 96-well plate).
[0127] Protein standard determination: first prepare protein standards with different concentration gradients (2, 1.5, 1, 0.75, 0.5, 0.25, 0.125, 0.025, 0 μg / μl), add 25 μl of the standard into a 96-well plate, and finally add 200 μl of the working solution, mix well, and incubate at 37°C for 30 min; measure the absorbance at 562 nm, and calculate the standard curve.
[0128] Sample determination: Sample to be tested: BCA working solution = 1:8, add 25μl sample to be tested, 200μl BCA working solution, mix well, place at 37℃ for 30min, and be careful to avoid bubbles. Measure the absorbance at 562nm, bring it into the standard curve, and calculate the protein concentration. Mix well according to the ratio of protein sample: 5× loading buffer = 4:1, place in a 100℃ metal bath for 10min, and store at -20℃.
[0129] (3) SDS-PAGE gel electrophoresis
[0130] Install the glass plate on the gel rack and add deionized water to check for leaks to avoid leakage. After checking for leaks, pour out the deionized water in the glass plate and dry it with filter paper. According to the molecular weight of the target protein, prepare 10 ml of 8%, 10% or 12% separation gel, and finally add ammonium persulfate and TEMED to promote coagulation. After vortexing and mixing, immediately pour the gel until the separation gel stops about 2 cm from the upper edge of the glass plate, and then slowly add anhydrous ethanol until it overflows. After the separation gel solidifies, pour out the anhydrous ethanol. Add the upper concentrated gel. Finally, add ammonium persulfate and TEMED to promote coagulation. After vortexing and mixing, immediately pour the gel and insert the comb teeth to avoid bubbles in the process. After the concentrated gel solidifies, install it in the electrophoresis tank, add 1× electrophoresis buffer, slowly pull out the comb teeth, and load the protein. Add Protein Maker (5μl) to one end of the protein sample, then turn on the power supply and perform electrophoresis at 80V for 20-30min. After the protein enters the separation gel, adjust the voltage to 120V and perform electrophoresis for about 60-70min.
[0131] (3) Transfer
[0132] Cut the filter paper and PVDF membrane in advance, activate the PVDF membrane in methanol for 2-5 minutes; then transfer the filter paper and PVDF membrane into pre-cooled 1× electro-transfer solution, cut the gel position of the target protein and the internal reference molecular weight according to the Maker's instructions, and use the "sandwich" method to place the sponge pad-filter paper-gel-PVDF membrane-filter paper-sponge pad in sequence, squeeze out the bubbles and place it in the transfer tank, and put an ice bag in the tank. The transfer conditions are 350mA constant current transfer for 30-40 minutes, and the transfer time is adjusted according to the protein molecular weight.
[0133] (4) Closed
[0134] Prepare blocking solution: Prepare 5% skim milk powder with TBST (2 g skim milk powder is dissolved in 40 ml TBST buffer). After the transfer is completed, take out the PVDF membrane and put it into the blocking solution, and block it at room temperature for 2 hours.
[0135] (5) Primary antibody incubation
[0136] After discarding the blocking solution, wash with TBST three times, 10 minutes each time, and add primary antibodies diluted in TBST; incubate at room temperature for 2 hours, or block overnight on a shaker at 4°C.
[0137] (6) Secondary antibody incubation
[0138] The primary antibody was recovered on the next day, and then washed three times with TBST, each time for 10 minutes, and the secondary antibody was added, blocked at room temperature for 2 hours, and washed three times with TBST, each time for 10 minutes.
[0139] (7) Development and result analysis
[0140] The strips were incubated with ECL luminescent solution at a ratio of solution A: solution B = 1:1, and the color exposure was performed using Image Lab software. The protein bands were analyzed using Image J software. The grayscale value of the target band was compared with the grayscale value of the internal reference band, and normalized with the control group for statistics to calculate the relative expression level of the target protein.
[0141] 9. Cellular transcriptome RNA-seq
[0142] (1) Total RNA extraction: cells with good logarithmic growth (previously treated with hyperoside for 24 h) were collected; blank control group and K562 cells treated with hyperoside (2 mM) for 24 h were collected. The cells were incubated at 1000 rpm for 5 min, washed 3 times with PBS, and then RNA was extracted.
[0143] (2) The total RNA extracted from the two groups of cells was sent to Ouyi Biotechnology Co., Ltd., and the total RNA of the cell samples was subjected to mRNA separation, fragmentation, double-stranded cDNA synthesis, cDNA fragment chemical modification, magnetic bead purification, fragmentation sorting and text amplification to meet the sequencing requirements.
[0144] (3) RNA sequencing and data analysis: The library obtained above was sequenced using the Illumina platform, and the sequencing results were analyzed to obtain the differentially expressed gene spectrum. The operation was completed by Ouyi Biotechnology.
[0145] 10. Determination of reduced glutathione (GSH) content
[0146] (1) After washing the collected cells with PBS for 2-3 times, the cells were collected at 1000 rpm for 5 min, 0.3-0.5 ml PBS was added to suspend the cells, and the cells were broken by ultrasonic grinding.
[0147] (2) Take 0.1 ml of the cell suspension after disruption, add 0.1 ml of the reagent, mix well, and centrifuge at 3500 rpm for 5 min. Take the supernatant for testing. Then add each reagent in sequence according to the instructions.
[0148] (3) The OD value at 405 nm was measured by an enzyme-labeled instrument and entered into the formula for calculation.
[0149] 11. Malondialdehyde (MDA) content and NADP (H) content determination
[0150] (1) After treatment, cells in each group were washed 2-3 times with PBS, and the cell pellets were collected and lysed by ultrasonication.
[0151] (2) Take a portion of the homogenate and measure the BCA concentration
[0152] (3) Follow the instructions provided by Nanjing Jiancheng Company and use an ELISA reader to measure the corresponding OD value. Substitute it into the formula and perform calculations.
[0153] 12. q-PCR detection of SLC7A11 and GPX4 mRNA levels
[0154] Total RNA was extracted using the Trizol method (all steps were performed on ice);
[0155] (1) Collect cells from different treatment groups, centrifuge at 1000 rpm for 5 min, discard the supernatant, and resuspend and wash twice with PBS.
[0156] (2) Add Trizol:chloroform in a ratio of 5:1, shake vigorously to mix, and place on ice for 10 min. Centrifuge at 4°C and 12,000 rpm for 15 min.
[0157] (3) Transfer the supernatant to a new centrifuge tube. Do not aspirate the precipitate.
[0158] (4) Add 500 μl of isopropanol to the supernatant, mix gently, let stand for 10 min, and centrifuge at 12,000 rpm for 15 min at 4°C.
[0159] (5) Discard the supernatant, add 75% ethanol, mix by inversion, wash the tube wall, centrifuge at 4°C, 12,000 rpm, for 10 min. Repeat the wash twice.
[0160] (6) After centrifugation, discard the alcohol and wait for the alcohol to dry with the mouth facing down. After drying, add 20-30 μl of DEPC water or RNase-free H2O to dissolve the RNA.
[0161] Reverse transcribe RNA into cDNA. The reverse transcription system is as follows:
[0162]
[0163] The reverse transcription procedure was as follows: incubate at 37°C for 2 min, incubate at 42°C for 10-20 min, and after the reaction was completed, incubate at 85°C for 5 s to terminate the reaction.
[0164] The gene amplification system is as follows:
[0165]
[0166] The whole reaction system is divided into two parts: amplification and melting curve. 2-△△Ct is used to indicate gene expression fold 13, and FerroOrange is used to detect intracellular Fe2+ level.
[0167] (1) Take the logarithmically growing cells, centrifuge at 1000 rpm for 5 minutes, replace the medium containing the drug, and culture in a 37°C, 5% CO2 incubator for 24 hours. Discard the supernatant and wash the cells 2-3 times with PBS.
[0168] (2) Dilute 1 mmol / l FerroOrange solution with serum-free culture medium to prepare 1 μmol / l FerroOrange working solution. Add 5 ml of the working solution to the cell suspension and culture in a 37°C, 5% CO2 incubator for 30 min.
[0169] (3) No need to wash, just observe directly. Slide the cell suspension onto a slide, observe under a microscope and take photos.
[0170] 14. Determination of C11-BODIPY lipid peroxidation level
[0171] (1) C11-BODIPY (581 / 591) was used to measure the level of lipid peroxidation in CML cells. After 24 h of Hyp drug intervention, 2 μM C11-BODIPY was added to the cells and incubated at 37°C for 30 min.
[0172] (2) Collect cells and centrifuge at 1000 rpm for 5 min. Take 20 μl of cell suspension for slide propagation.
[0173] (3) After drying, observe and take photos using a confocal microscope.
[0174] 15. Observation of mitochondrial structure of CML cells using transmission electron microscopy
[0175] (1) After K562 and Meg-01 cells were treated with hyperoside (0, 2 mM) for 24 h, the cells were collected in a 15 ml centrifuge tube, centrifuged at 1500 rpm for 5 min, the cell supernatant was discarded, and the cells were washed three times with PBS (no less than 106 cells / sample), transferred to a 1.5 ml EP tube, and centrifuged to remove PBS.
[0176] (2) Slowly add electron microscopy fixative and resuspend at 4°C for 2-4 hours. Store at 4°C.
[0177] (3) The cells are then embedded, fixed, and polymerized before staining.
[0178] (4) Observe under a transmission electron microscope and collect images for analysis.
[0179] 16. ROS level detection: After collecting cells, load the probe, dilute DCFH-DA with serum-free medium at 1:1000 to a concentration of 10μmol / l, collect cells and centrifuge at 1000rpm for 5 minutes, discard the supernatant, add the probe, and incubate in an incubator in the dark for half an hour. Mix well in the middle to avoid insufficient contact between cells and DCFH-DA probe. Wash with PBS 2-3 times, take the cell suspension for slide, take pictures under a microscope, and randomly take more than 3 different fields of view.
[0180] 17. Detection of Mitosox levels: CML cells were collected, incubated with 5 μmol / L mitochondrial superoxide indicator Mitosox in a 37°C incubator for 10 min, washed 2-3 times with PBS, and photographed and recorded under a microscope.
[0181] in conclusion:
[0182] 1. Effect of Hyperoside on CML cell growth:
[0183] 1. Hyperoside inhibits the cell viability and migration of K562 and Meg-01 cells: The results of CCK8 experiments suggest that the inhibitory effect of Hyperoside on the viability of K562 and Meg-01 cells is concentration- and time-dependent ( Figure 1 A. Figure 1 B. Figure 1 C and Figure 1 D). In addition, in the present invention, in order to further illustrate the inhibitory effect of Hyperoside on CML cells, the Transwell results suggest that after intervention with different concentrations of Hyperoside (0, 0.5, 1, 2 mM) for 24 hours, it was found that the inhibitory effect of Hyperoside on the migration ability of K562 and Meg-01 cells was concentration-dependent ( Figure 1 E and Figure 1 F)
[0184] 2. Hyperoside inhibits the proliferation of K562 and Meg-01 cells: The results of the EDμ-594 cell proliferation experiment showed that after different concentrations of Hyperoside (0, 0.5, 1, 2 mM) were used to intervene in the cells for 24 hours, it was found that Hyperoside could inhibit the EDU positive rate of K562 and Meg-01 cells, that is, inhibit the proliferation of K562 and Meg-01 cells, and it was concentration-dependent ( Figure 2 A. Figure 2 B. Figure 2 C and Figure 2 D).
[0185] 3. Hyperoside induces apoptosis of K562 and Meg-01 cells: Flow cytometry was used to detect the apoptosis rate of each group. The results showed that when Hyperoside at different concentrations (0, 0.5, 1 and 2 mM) intervened in CML cells for 24 h, the apoptosis rates of K562 cells were (4.3%, 13%, 17.9% and 44.2%), and the apoptosis rates of Meg-01 cells were (4.0%, 10.9%, 18.2% and 42.3%), indicating that with the increase of Hyperoside drug concentration, CML cells can be induced to undergo apoptosis in a concentration-dependent manner ( Figure 3 A. Figure 3 B. Figure 3 C and Figure 3 D).
[0186] In addition, in order to further clarify the effect of Hyperosid on CML cell apoptosis in the present invention, the changes in the expression of apoptotic proteins (Bcl-2, Bax and Caspase-3) were detected by Western blotting: Hyperosid can significantly lead to the downregulation of anti-apoptotic protein Bcl-2 in K562 and Meg-01 cells, and the increase of the expression of pro-apoptotic proteins Bax and Caspase-3, indicating that the pro-apoptotic effect on CML cells is concentration-dependent ( Figure 3 E. Figure 3 F. Figure 3 G and Figure 3 H).
[0187] According to the above results, Hyperoside can inhibit the growth of CML cells.
[0188] (II) Hyperoside's inhibitory effect on chronic myeloid leukemia cells is related to ferroptosis
[0189] K562 cell transcriptome sequencing and target gene screening: In order to further explore the mechanism of action of hyperoside on chronic myeloid leukemia cells, we selected a control group and a Hyperoside (2mM) concentration group for transcriptome sequencing data analysis. Three replicate samples were sent to each group. The PCA graph showed that there was a significant difference between the two groups ( Figure 4 A). KEGG pathway enrichment analysis showed that differentially expressed genes were enriched in the ferroptosis pathway ( Figure 4 B). Compared with the control group, the volcano plot of the hyperoside (2mM) group showed that 1033 genes were significantly upregulated and 605 genes were significantly downregulated ( Figure 4 C). Among the differentially expressed genes, SLC7A11 and GPX4 were downregulated ( Figure 4D and 4E). The changes in protein and mRNA expression of ferroptosis markers (SLC7A11 and GPX4) were detected by Western blotting and qRT-PCR. Hyperoside intervention led to a significant downregulation of SLC7A11 and GPX4 levels ( Figure 4 F. Figure 4 G. Figure 4 H. Figure 4 I and Figure 4 J).
[0190] In addition, since the pathogenesis of CML is complex and involves autophagy, apoptosis, necrosis, etc., in the examples of the present invention, Z-VAD-FMK (apoptosis inhibitor), necrosulfonamide (necrosis inhibitor), 3-Mmethyladenine (3-MA, autophagy inhibitor), and Fer-1 (ferroptosis inhibitor) were added to different concentrations of Hyperoside (0, 0.5, 1, and 2 mM) in vitro, and the viability of CML cells was detected after 24 and 48 hours of intervention to further explore the effect of Hyperoside on CML.
[0191] The effect of Hyperoside on CML cell viability is mainly related to ferroptosis: CCK-8 results showed that Z-VAD-FMK and Fer-1 could weaken the inhibitory effect of hyperoside, and the effect of ferroptosis inhibitor Fer-1 was more significant, while necrosulfonamide and 3-MA could not block the inhibitory effect of Hyperoside on CML cell viability. It can be seen that ferroptosis plays an important role in the treatment of CML by Hyperoside ( Figure 5 A and Figure 5 B).
[0192] Hyperoside promotes lipid peroxidation and ROS levels in K562 and Meg-01 cells: C11-BODIPY and intracellular ROS fluorescence staining showed that Hyperoside significantly enhanced lipid peroxidation and ROS levels in CML cells ( Figure 6 A. Figure 6 B. Figure 6 C. Figure 6 D. Figure 6 E and Figure 6 F).
[0193] In addition, since the NADPH / NADP+ ratio is the main indicator of the cell's redox state, the consumption of glutathione (GSH) and the accumulation of malondialdehyde (MDA) are also necessary factors for ferroptosis. The results showed that Hyperoside can reduce the cell ratios of NADPH / NADP+ and GSH / GSSG in K562 and Meg-01 cells and increase the level of MDA, which further indicates that Hyperoside can increase the level of oxidative stress in K562 and Meg-01 cells and promote ferroptosis ( Figure 6 G. Figure 6 H. Figure 6 I).
[0194] Hyperoside can increase the accumulation of Fe2+ in K562 and Meg-01 cells: Fe2+ probe FerroOrange detection suggests that Hyperoside intervention leads to an increase in the fluorescence intensity of FerroOrange in K562 and Meg-01 cells, indicating that Fe2+ accumulation in CML cells increases ( Figure 7 A. Figure 7 B. Figure 7 C and Figure 7 D).
[0195] Effects of Hyperoside on mitochondrial changes in K562 and Meg-01 cells: Mitosox results suggest that Hyperoside significantly enhances mitochondrial ROS levels in CML cells, further indicating that Hyperoside can increase oxidative stress levels in K562 and Meg-01 cells ( Figure 8 A. Figure 8 B. Figure 8 C and Figure 8 D). In addition, the changes in mitochondrial structure were observed using transmission electron microscopy (TEM). The results showed that after 24 hours of intervention with Hyperoside in CML cells, the mitochondrial volume and cristae of K562 and Meg-01 cells decreased, and the membrane density increased, which are the mitochondrial morphological characteristics of ferroptosis ( Figure 8 E and Figure 8 F).
[0196] In summary, Hyperoside can inhibit the growth of CML cells by promoting the occurrence of ferroptosis.
[0197] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.
Claims
1. Application of hyperoside in the preparation of drugs for inhibiting chronic myeloid leukemia.
2. Use of hyperoside according to claim 1 in the preparation of a drug for inhibiting chronic myeloid leukemia, It is characterized in that Applications include: application of hyperoside in the preparation of drugs for inhibiting the growth of chronic myeloid leukemia cells, wherein the chronic myeloid leukemia cells include K562 and Meg-01.
3. Use of hyperoside according to claim 2 in the preparation of a drug for inhibiting chronic myeloid leukemia, It is characterized in that Applications include: Application of hyperoside in the preparation of drugs for inhibiting the viability and migration ability of chronic myeloid leukemia cells.
4. Use of hyperoside according to claim 2 in the preparation of a drug for inhibiting chronic myeloid leukemia, It is characterized in that Applications include: Application of hyperoside in the preparation of drugs for inhibiting proliferation of chronic myeloid leukemia cells.
5. Use of the hyperoside according to claim 2 in the preparation of a drug for inhibiting chronic myeloid leukemia, It is characterized in that Applications include: Application of hyperoside in the preparation of drugs for inhibiting apoptosis of chronic myeloid leukemia cells.
6. Use of the hyperoside according to claim 2 in the preparation of a drug for inhibiting chronic myeloid leukemia, It is characterized in that The main target of hyperoside in the preparation of drugs for inhibiting the growth of chronic myeloid leukocytes is related to ferroptosis.
7. Use of the hyperoside according to claim 2 in the preparation of a drug for inhibiting chronic myeloid leukemia, It is characterized in that Application of hyperoside in the preparation of drugs for enhancing lipid peroxidation and ROS levels in chronic myeloid leukemia cells and increasing intracellular oxidative stress levels.
8. Use of the hyperoside according to claim 2 in the preparation of a drug for inhibiting chronic myeloid leukemia, It is characterized in that Application of hyperoside in the preparation of drugs for enhancing Fe2+ accumulation in chronic myeloid leukemia cells.
9. Use of the hyperoside according to claim 2 in the preparation of a drug for inhibiting chronic myeloid leukemia, It is characterized in that Application of hyperoside in drugs for improving mitochondrial structure in chronic myeloid leukemia cells.
